Bengaluru’s OneSource Pharma Eyes $ 500 M Revenue In The Middle Of License High Cliff
Bengaluru-based OneSource Specialty Pharma, a CDMO demerged from Strides Pharma in 2024, is positioned for rapid development, projecting $ 500 million in profits by FY 28 with 40 % EBITDA margins. This rise aligns with the coming close to expiry of semaglutide licenses and the burgeoning GLP- 1 market.
- Growth Motorists: The company’s development is sustained by Drug-Device Combinations, especially GLP- 1 shot pens.
- Ability Development: Significant capital expenditure will certainly raise cartridge capacity to 220 million devices by FY 27, sustained by long-lasting agreements.
- Regulatory Benefit: OneSource’s USFDA-approved Bengaluru center offers biologics fill-finish and gadget assembly abilities.